---
title: "Did Cytokinetics, Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CYTK"
description: "Levi & Korsinsky has launched an investigation into Cytokinetics, Incorporated for potential violations of federal securities laws. This follows a report indicating that the FDA has delayed the approv"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238997509.md"
published_at: "2025-05-06T22:45:32.000Z"
---

# Did Cytokinetics, Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CYTK

> Levi & Korsinsky has launched an investigation into Cytokinetics, Incorporated for potential violations of federal securities laws. This follows a report indicating that the FDA has delayed the approval of Cytokinetics' drug aficamten, leading to a 12% drop in the company's stock. The firm, known for its expertise in securities litigation, aims to protect investors' rights.

**NEW YORK, NY / ACCESS Newswire / May 6, 2025 /** Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") concerning possible violations of federal securities laws.

BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan."

Following this news, Cytokinetics' stock dropped over 12% during afternoon trading on that same day. To obtain additional information, go to:

https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=147211&wire=1

or contact Joseph E. Levi, Esq.

**WHY LEVI & KORSINSKY:** Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

**SOURCE:** Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire

### Related Stocks

- [CYTK.US - Cytokinetics](https://longbridge.com/en/quote/CYTK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cytokinetics Reports Aficamten Outperforms Metoprolol in HCM Exercise Capacity Trial | Cytokinetics Incorporated announced new data from the MAPLE-HCM clinical trial, which showed that aficamten outperformed | [Link](https://longbridge.com/en/news/265150290.md) |
| Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens | Cytokinetics reported a Q3 net loss of $306.2 million, attributed to debt conversion expenses, despite a revenue increas | [Link](https://longbridge.com/en/news/264497991.md) |
| Pomerantz LLP Issues Reminder to Shareholders in Cytokinetics, Incorporate of Class Action Filing – CYTK | Pomerantz LLP has announced a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful  | [Link](https://longbridge.com/en/news/265405800.md) |
| 03:13 ET
			
			
				CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm | The Schall Law Firm is reminding investors of a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK) f | [Link](https://longbridge.com/en/news/265287432.md) |
| Class Action Reminder from Pomerantz LLP for Investors of Cytokinetics, Incorporate – CYTK | Pomerantz LLP has filed a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud. Investors are en | [Link](https://longbridge.com/en/news/265187854.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.